Clinical Trials Logo

Adenocarcinoma Esophagus clinical trials

View clinical trials related to Adenocarcinoma Esophagus.

Filter by:
  • None
  • Page 1

NCT ID: NCT06044311 Not yet recruiting - Clinical trials for Adenocarcinoma Esophagus

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This interventional clinical trial aims to find ways of improving treatments for individuals with esophageal cancer. Laboratory-based studies show that using medicines that affect a protein called TGF-beta (TGFβ) can kill esophageal cancer cells in individuals who have localized esophageal adenocarcinoma and are being considered for standard-of-care chemoradiation prior to surgery. Participants of this study will take a pill called vactosertib for two weeks before starting standard of care chemoradiation. At the end of the two weeks of taking vactosertib, participants will have a Positron Emission Tomography Computer Assisted Tomography (PET CT) scan and undergo an endoscopy with a biopsy to determine if the vactosertib is working. After chemoradiation, participants will take vactosertib again for four weeks and then be considered for surgery.

NCT ID: NCT05067842 Recruiting - Clinical trials for Adenocarcinoma Esophagus

Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma

TRACT DNA
Start date: May 13, 2022
Phase:
Study type: Observational [Patient Registry]

This is an observational study to determine the feasibility of assessing tumor response utilizing ctDNA in patients of locally advanced esophageal and gastroesophageal junction (LA-EA/GEJ) cancer undergoing total neoadjuvant therapy (TNT) consisting of systemic chemotherapy (modified FOLFOX or FLOT/DFOX) followed by concurrent chemoradiation [50.4 Gray (Gy) over approximately six weeks with concurrent radio sensitizing dose of carboplatin/paclitaxel].

NCT ID: NCT04818476 Recruiting - Barrett Esophagus Clinical Trials

Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus

Start date: February 10, 2020
Phase:
Study type: Observational

The purpose of this study is to assess lymph node metastasis rate, distant metastasis rate, disease-specific mortality, and overall mortality in patients with Barrett's related T1b and high risk T1a esophageal adenocarcinoma (EAC) who underwent a diagnostic endoscopic resection.

NCT ID: NCT04028167 Recruiting - Clinical trials for Adenocarcinoma of the Gastroesophageal Junction

Induction FLOT With CROSS CRT for Esophageal Cancer

Start date: April 8, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates a novel regimen of induction chemotherapy using a combination of docetaxel, oxaliplatin, and leucovorin, with short term infusional 5-FU (FLOT), given prior to chemoradiotherapy with concurrent carboplatin and paclitaxel, as neoadjuvant therapy prior to definitive surgical resection for patients with adenocarcinoma of the esophagus or gastroesophageal junction

NCT ID: NCT02991547 Terminated - Clinical trials for Adenocarcinoma Esophagus

Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus

SAGE
Start date: December 2016
Phase:
Study type: Observational

The purpose of this study is to find out more information about patients who have cancer (adenocarcinoma) of the esophagus or gastroesophageal junction (GEJ) who have been treated with chemotherapy and radiation but have not had surgery. The study will follow patients for 5 years to monitor for their cancer and to see how the standard medical care affects the daily life of patients.

NCT ID: NCT02971956 Completed - Esophageal Cancer Clinical Trials

Pembrolizumab in Refractory Advanced Esophageal Cancer

Start date: January 18, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab